- ￥990 - 5912
- Solarbio
- 北京
- IC3680
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
C188-9
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
432001-19-9
- 规格：
100mg/50mg/25mg/10mg/5mg
| 规格： | 100mg | 产品价格： | ￥5912.0 |
|---|---|---|---|
| 规格： | 50mg | 产品价格： | ￥4220.0 |
| 规格： | 25mg | 产品价格： | ￥2690.0 |
| 规格： | 10mg | 产品价格： | ￥1235.0 |
| 规格： | 5mg | 产品价格： | ￥990.0 |
是一种新型，有效的STAT3抑制剂
| 基本信息 | |
| CAS | No.432001-19-9 |
| 英文名称 | C188-9 |
| 别名 | TTI-101 |
| 分子式 | C27H21NO5S |
| 分子量 | 471.52 |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Off-white to brown Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| MDL | MFCD03141581 |
| SMILES | O=S(C1=CC=C(OC)C=C1)(NC2=C3C=CC=CC3=C(O)C(C4=C5C=CC=CC5=CC=C4O)=C2)=O |
| InChIKey | QDCJDYWGYVPBDO-UHFFFAOYSA-N |
| InChI | InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3 |
| PubChem CID | 1324494 |
| 靶点 | STAT3 |
| 通路 | JAK/STAT Signaling |
| 背景说明 | C188-9是一种新型,有效的STAT3抑制剂。 |
| 生物活性 | C188-9 (TTI-101) is a STAT3 inhibitor, with a Kd of 4.7 nM. C188-9 inhibits G-CSF-induced STAT3 activation and STAT3-dependent gene expression. C188-9 induces apoptosis in AML cell lines and primary samples and inhibits colony formation by primary AML blasts[1-4]. |
| In Vitro | C188-9 is a Stat3 inhibitor，with a Kd of 4.7 nM[1]. The IC50s of C188-9 to inhibit Stat3 activation in AML cell lines are in the range of 4-7 μM，and in primary AML samples the IC50s are in the range of 8-18 μM. For apoptosis studies，AML cell lines and primary samples are treated for 24 hours with C188-9，then apoptotic cells are quantified by FACS analysis for annexin V-labeled cells. The EC50s for apoptosis induction are quite variable，ranging from 6 μM to over 50 μM[2]. |
| 细胞实验 | Of the approximately 13，528 discernible genes，levels of 37 gene transcripts are altered by C188(17 down and 20 up-regulated，fdr <0.01，fold change≥1.5)，of which 7 are known STAT3 gene targets. In comparison，C188-9 affects a much greater number of genes involved in oncogenesis(384 total，95 down- and 289 up-regulated)，including 76 genes previously reported as regulated by STAT3(38 down-regulated and 38 up-regulated). Among the 38 genes previously shown to be upregulated by STAT3，24(63%)genes are downregulated by C188-9 treatment，as expected. Additionally，10 more genes downregulated by C188-9(fdr <0.01，fold change≥1.5)that previously are shown to be upregulated by STAT1. Thus，40 of 48(83.3%)genes downregulated by C188-9 previously are shown to be positively regulated by STAT1，including sixteen genes shown to be co-regulated by STAT3 and STAT1. This analysis raises the possibility that the effect of C188-9 on gene transcript levels in HNSCC tumors is mediated by its effects on both STAT3 and STAT1[3]. |
| 细胞实验 | Cell lines are plated at 2 to 5×105 cells/mL in growth medium and treated with increasing doses of inhibitor for 24 hours. CD34+ AML cells are plated at 1 to 2×105 cells/mL in IMDM with 20% FBS and Pen/Strep，and incubated with C188-9(0.3 to 100 μM)for 48 hours. Cells are then harvested and labeled. The fraction of spontaneous apoptosis is determined from an untreated sample and then subtracted from the drug-treated samples to yield the percentage of apoptosis attributed to drug treatment[1]. |
| 动物实验 | UM-SCC-17B cells(1.5×106)are injected into the tongues of athymic，8-10 week old，male，nude mice. Once tumors are established，mice(20 total; 10/group)are randomized(average tumor vol ~15-20 mm3)to receive 5 times a week，intraperitoneal injections of either DMSO or C188(50 mg/kg)or C188-9(100 mg/kg). Tumor volumes are measured twice weekly. Average tumor volumes 6/πx(long dimension)x(short dimension)2))are calculated and normalized to the volume at first day of treatment and plotted comparison is done by t test(* p<0.05)[3]. |
| 数据来源文献 | [1]. Silva KA， et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system， leading to preservation of muscle mass in cancer cachexia. J Biol Chem. 2015 Apr 24;290(17):11177-87. [2]. Redell MS， et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011 May 26;117(21):5701-9. [3]. Bharadwaj U， et al. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget. 2016 May 3;7(18):26307-30. [4]. Redell MS， et al. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011;117(21):5701-5709. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
CDllb 常用单克隆抗体或代号：Mol，OKM1；(Macl，CR3，整合素αM) 主要表达细胞：G，M，T， B， DC， NK，Mac[AS] 分子质量(kDa)和结构：gp170(整合素α) 功 能：iC3b和Fs受体，与ICAM-l和X因子结合，黏附，调理吞噬；结合JAM-3 CDllc 常用单克隆抗体或代号：LeuM乳(CR4．整合素αX) 主要表达细胞：M，G，B
2F+DwTquooTcizAj6Sh40arj1e+iWJ2ispgsbT801bWi9OaaVDQ0u7N9Rf22Q7je3ypEkT/aXtAx/4gHh20RbetchuWXizve3YY/3L0LGHHqt8Cva+97zf/vEfvyYb4imWXpTxLz8m4rvgjodswc3X26Xnn2o3LbjZPv/Fv5GGuGa33/ZzO2n2HD17NAEWeUXwmQh44uy32U+uutL+69e+6jjedfsddvSxx3m8xNNFQ67wipqQKHyESZ35
5+YiLLj4HREBXstjztk7uH3PDncf2sPhxRlMq6wGF+vZ2OlE8VGoBH85gWn/XYBn2ck48eAqDu+xwjbrU7h2Zz2aZ3fD6YWWeBFuzJv2yfAMMyYBFj4y5r7yqpgAE0jPBFRyolzbpihAeo1X9z5K2o2YlqOUxRTN25rQLQ+8+x4oVfFzvgFHklZM2raEadaIsxjVfI0wedUizB5fB7r8yR8TTr6mQAL8FlQgbB6KCTABJiAfgWD8ev0cIrh
技术资料暂无技术资料 索取技术资料
IC3680 C188-9 抑制剂/拮抗剂/激动剂 索莱宝
￥990 - 5912
